Contact:
Jason Merrill
314-286-0302
[email protected]
April 28, 2010, ST. LOUIS - To help improve the availability of breast cancer screening, treatment, education and research in the St. Louis area, the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine was awarded five grants from the St. Louis Affiliate of Susan G. Komen for the Cure®.
Funding for these programs is made possible because of the more than $3.25 million raised from the 2009 Susan G. Komen St. Louis Race for the Cure® as well as other affiliate fundraising throughout the year. Of the net proceeds raised locally by the Komen St. Louis Affiliate, a minimum of 25% goes to national Susan G. Komen for the Cure® Grants Program for research and up to 75% stays in St. Louis to help organizations provide breast cancer screening, treatment, education and research programs.
2010 Komen Funded Programs at the Siteman
-The Daylight Program
The Daylight Project is a multidisciplinary effort of the Barnes-Jewish Hospital Refugee Health Service. The program delivers linguistically and culturally appropriate education about breast health promotion and the benefits of early detection of breast cancer.
-The Navigator Project
The goals of the program are to decrease the time from a biopsy showing breast cancer to initiation of treatment by providing counseling, practical support and removing barriers to care.
-Navigating the Safety Net: Paving Smooth Pathways to Care for Underserved People
This program will care for more than 2,600 underserved, low income people in all counties served by the Komen St. Louis Affiliate. It will provide services along the complete trajectory of breast care, from outreach and screening through follow- up, diagnosis, and treatment
Also, two 2010 CRAFT Grant Awards funding clinical trials research were awarded to D. Craig Allred, MD, professor of pathology & immunology to for “Breast Cancer Resource to Study Prevention in African American Women (SPAA)” and to To Cynthia X. Ma, MD, PhD, Assistant Professor of Medicine for a Phase I/II Trial of Letrozole in Combination with MK2206 in Clinical Stage II or III Estrogen Receptor Positive and HER2 Negative Breast Cancer.